Simrat Randhawa

EVP R&D Simrat Randhawa sells 26,530 shares ($2.4M) via 10b5-1 plan; retains 4,000 shares + 209,076 in derivatives.

Simrat Randhawa, EVP and Head of R&D at Dianthus Therapeutics, executed three separate sales totaling 26,530 shares for $2,404,076.95 at a blended average price of $90.62 on 2026-06-01. This transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2025-08-14, meaning the sales were scheduled rather than discretionary. The insider's non-derivative holdings fall from 30,530 shares to 4,000 shares, representing a reduction of 86.9%, while substantial derivative holdings (209,076 shares across four stock options) remain post-transaction. At the current price of $81.57, the stock trades 15.5% below its 52-week high of $96.50, having declined 6.7% over the past 30 days despite a 31.5% gain over the past 90 days. The company reported revenue of $396,000.00 in the latest quarter, a net loss of $40,834,000.00, and annual revenue growth of -67.4%, with no profitability over its most recent full fiscal year. Prior sales by this insider at DNTH over the last eight months have consistently produced positive subsequent returns: a +10.2% 30-day return on the 2026-03-12 sale and multi-month returns ranging from +9.8% to +39.4% on five trades between November 2025 and March 2026. The scheduled nature of this divestment under a 10b5-1 plan precludes timing-based inference, but the context—significant share reduction paired with retained derivative exposure, severe revenue contraction, and ongoing losses—warrants attention to operational fundamentals.

EVP R&D Randhawa sold entire 33,830-share stake at $81.48 under 10b5-1 plan; zero shares remain

Simrat Randhawa, EVP and Head of R&D at Dianthus Therapeutics, executed a complete exit of his equity holdings, selling 33,830 shares for $2,756,468.40 on 2026-03-12. This transaction was executed under a pre-arranged 10b5-1 trading plan adopted on 2025-08-14, meaning the sale was scheduled in advance rather than discretionary. The elimination of his entire position eliminates an insider's ongoing financial alignment with the company's performance; however, the pre-arranged nature of the transaction precludes attribution to recent business developments or near-term outlook shifts. The post-transaction holding of 0 shares represents a complete dissolution of directly held equity exposure by a senior R&D executive.

EVP Head of R&D Randhawa sold 196,538 shares for $7,379,887.46 via pre-arranged 10b5-1 plan

Randhawa Simrat, EVP and Head of R&D at Dianthus Therapeutics, executed four separate sales totaling 196,538 shares for $7,379,887.46 at blended average price of $37.55 on November 13-14, 2025. This transaction was executed under a 10b5-1 trading plan adopted on 2025-08-14, making it a scheduled, non-discretionary activity. Post-transaction holdings total 4,000 shares, representing a reduction of 196,538 shares (-98.0% vs pre-transaction holdings of 200,538 shares), leaving the executive with minimal retained equity stake in the company. The magnitude of this liquidation—divesting nearly all share holdings—represents a material change in insider ownership position at an R&D-focused therapeutic company.